AR109533A2 - Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios - Google Patents

Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios

Info

Publication number
AR109533A2
AR109533A2 ARP170102555A ARP170102555A AR109533A2 AR 109533 A2 AR109533 A2 AR 109533A2 AR P170102555 A ARP170102555 A AR P170102555A AR P170102555 A ARP170102555 A AR P170102555A AR 109533 A2 AR109533 A2 AR 109533A2
Authority
AR
Argentina
Prior art keywords
antibody
fkn
cdr
seq
amino acid
Prior art date
Application number
ARP170102555A
Other languages
English (en)
Inventor
Toshio Imai
Tetsu Kawano
Yoshimasa Sakamoto
Miyuki Nishimura
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR109533(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR109533A2 publication Critical patent/AR109533A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Reivindicación 1: Un anticuerpo anti-fractalkina o un fragmento de unión a la FKN de éste, caracterizados porque el anticuerpo o el fragmento de éste comprenden (a) una CDR-H1 que comprende la secuencia de aminoácidos de SEQ ID Nº 28; (b) una CDR-H2 que comprende la secuencia de aminoácidos de SEQ ID Nº 29; (c) una CDR-H3 que comprende la secuencia de aminoácidos de SEQ ID Nº 30; (d) una CDR-L1 que comprende la secuencia de aminoácidos de SEQ ID Nº 31; (e) una CDR-L2 que comprende la secuencia de aminoácidos de SEQ ID Nº 32; y (f) una CDR-L3 que comprende la secuencia de aminoácidos de SEQ ID Nº 33. Reivindicación 14: Una composición farmacéutica caracterizada porque comprende el anticuerpo o el fragmento de unión a la FKN del anticuerpo de cualquiera de las reivindicaciones 1 - 13. Reivindicación 17: Un ácido nucleico caracterizado porque codifica el anticuerpo o el fragmento de unión a la FKN del anticuerpo de cualquiera de las reivindicaciones 1 - 13. Reivindicación 20: Un vector caracterizado porque comprende el ácido nucleico de cualquiera de las reivindicaciones 17 - 19. Reivindicación 23: La célula huésped de la reivindicación 22, caracterizada porque dicha célula huésped comprende un primer vector y un segundo vector, donde dicho primer vector comprende un ácido nucleico que codifica una cadena pesada y dicho segundo vector comprende un ácido nucleico que codifica una cadena liviana del anticuerpo o el fragmento de unión a la FKN del anticuerpo de cualquiera de las reivindicaciones 1 - 13. Reivindicación 32: Un método para tratar un trastorno inflamatorio, caracterizado porque comprende administrarle una cantidad eficaz del anticuerpo o el fragmento de unión a la FKN del anticuerpo de cualquiera de las reivindicaciones 1 - 13 a un sujeto que necesita dicho tratamiento, con lo que se trata el trastorno inflamatorio.
ARP170102555A 2009-10-30 2017-09-15 Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios AR109533A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30

Publications (1)

Publication Number Publication Date
AR109533A2 true AR109533A2 (es) 2018-12-19

Family

ID=43922220

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103947A AR078796A1 (es) 2009-10-30 2010-10-28 Composiciones y metodos para tratar trastornos inflamatorios
ARP170102555A AR109533A2 (es) 2009-10-30 2017-09-15 Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100103947A AR078796A1 (es) 2009-10-30 2010-10-28 Composiciones y metodos para tratar trastornos inflamatorios

Country Status (33)

Country Link
US (1) US8932592B2 (es)
EP (1) EP2493930B1 (es)
JP (2) JP5631991B2 (es)
KR (2) KR101627605B1 (es)
CN (1) CN102597003B (es)
AR (2) AR078796A1 (es)
AU (1) AU2010312408B2 (es)
BR (1) BR112012010266A2 (es)
CA (1) CA2778895C (es)
CL (2) CL2012001143A1 (es)
CY (1) CY1121167T1 (es)
DK (1) DK2493930T3 (es)
ES (1) ES2698389T3 (es)
HR (1) HRP20181973T1 (es)
HU (1) HUE041952T2 (es)
IL (1) IL219470A (es)
JO (1) JO3437B1 (es)
LT (1) LT2493930T (es)
MX (1) MX2012005052A (es)
MY (1) MY158481A (es)
NZ (1) NZ599779A (es)
PE (1) PE20121645A1 (es)
PH (1) PH12012500828A1 (es)
PL (1) PL2493930T3 (es)
PT (1) PT2493930T (es)
RS (1) RS58142B1 (es)
RU (1) RU2569109C2 (es)
SI (1) SI2493930T1 (es)
SM (1) SMT201800637T1 (es)
TW (1) TWI414308B (es)
UA (1) UA105073C2 (es)
WO (1) WO2011052799A1 (es)
ZA (1) ZA201203002B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
LT3221346T (lt) 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
WO2020214166A1 (en) * 2019-04-17 2020-10-22 The Governors Of The University Of Alberta Treatment of autoimmune liver disease
US20220205980A1 (en) * 2019-04-23 2022-06-30 Eisai R&D Management Co., Ltd. Biomarker for rheumatoid arthritis treatment
US20230043034A1 (en) * 2019-12-09 2023-02-09 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
TW202227483A (zh) 2020-10-30 2022-07-16 日商衛材R&D企管股份有限公司 醫藥組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1994029351A2 (en) * 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
WO1997027299A1 (en) 1996-01-24 1997-07-31 Schering Corporation Mammalian cx3c chemokine genes
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
JP2002503951A (ja) 1996-05-07 2002-02-05 ミレニアム ファーマシューティカルズ インク． ニューロタクチンおよびその使用
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US6420121B1 (en) 1998-08-31 2002-07-16 Oregon Health Sciences University Prevention of cell migration initiation with CMV US28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2001060406A1 (en) 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20020192212A1 (en) 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
WO2003018549A2 (en) 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
JPWO2005032589A1 (ja) 2003-10-02 2007-11-15 独立行政法人科学技術振興機構 Ｇｖｈｄの予防及び治療
MXPA06003792A (es) 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
WO2006033386A1 (ja) * 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG4抗体
JP4979388B2 (ja) 2004-10-29 2012-07-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性疾患治療剤
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
ES2410886T3 (es) * 2006-10-26 2013-07-03 Janssen Biotech, Inc. Métodos para la adaptación al ser humano de anticuerpos monoclonales
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.

Also Published As

Publication number Publication date
CL2012001143A1 (es) 2012-10-05
MY158481A (en) 2016-10-14
JP5631991B2 (ja) 2014-11-26
TW201127401A (en) 2011-08-16
CY1121167T1 (el) 2020-05-29
RU2012122203A (ru) 2013-12-10
IL219470A0 (en) 2012-06-28
HUE041952T2 (hu) 2019-06-28
EP2493930A1 (en) 2012-09-05
SI2493930T1 (sl) 2018-12-31
KR102099596B1 (ko) 2020-04-10
RU2569109C2 (ru) 2015-11-20
AR078796A1 (es) 2011-12-07
US8932592B2 (en) 2015-01-13
CN102597003B (zh) 2016-03-23
AU2010312408A1 (en) 2012-06-21
SMT201800637T1 (it) 2019-01-11
JP2015027304A (ja) 2015-02-12
PL2493930T3 (pl) 2019-03-29
DK2493930T3 (en) 2018-12-17
NZ599779A (en) 2014-03-28
KR20120104560A (ko) 2012-09-21
UA105073C2 (uk) 2014-04-10
AU2010312408B2 (en) 2015-07-09
JP2013509158A (ja) 2013-03-14
CL2015000114A1 (es) 2015-04-10
WO2011052799A1 (en) 2011-05-05
RS58142B1 (sr) 2019-02-28
HRP20181973T1 (hr) 2019-01-25
PE20121645A1 (es) 2012-12-06
CA2778895A1 (en) 2011-05-05
ES2698389T3 (es) 2019-02-04
LT2493930T (lt) 2019-01-10
IL219470A (en) 2017-10-31
JO3437B1 (ar) 2019-10-20
US20120213799A1 (en) 2012-08-23
ZA201203002B (en) 2013-06-26
TWI414308B (zh) 2013-11-11
BR112012010266A2 (pt) 2016-12-06
EP2493930B1 (en) 2018-09-19
PH12012500828A1 (en) 2013-01-07
CN102597003A (zh) 2012-07-18
KR20160066055A (ko) 2016-06-09
CA2778895C (en) 2018-08-07
EP2493930A4 (en) 2013-12-04
PT2493930T (pt) 2018-11-29
MX2012005052A (es) 2012-05-29
KR101627605B1 (ko) 2016-06-07

Similar Documents

Publication Publication Date Title
AR109533A2 (es) Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
AR080501A1 (es) Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1)
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
AR084141A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
AR083747A1 (es) Anticuerpos anti-il-23
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20130159A1 (es) Anticuerpos anti-cd40
TW200745164A (en) Gene recombination antibodies composition
PE20131209A1 (es) Anticuerpos anti-fap
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
AR108034A1 (es) Moléculas de unión a ror1, y métodos de uso de las mismas
PE20121646A1 (es) Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
PE20212324A1 (es) Anticuerpos que reconocen tau
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
AR110659A1 (es) Proteínas de unión a antígenos anti-neuropilin y método para su uso
AR075849A1 (es) Moleculas de anticuerpos que tienen especificidad de union por il-13 humana
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
PE20080214A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana

Legal Events

Date Code Title Description
FB Suspension of granting procedure